Memphasys Adds Poland to Its European Expansion Map

Memphasys has taken another step towards turning its Felix sperm-selection technology into a recurring commercial business, securing an exclusive distribution agreement with Warsaw-based TK Biotech.

The deal carries a minimum contracted value of about €212,000, equivalent to roughly A$350,000, across a two-year commercial term. Poland becomes the third European market where Felix has achieved sales or a commercial agreement, following Italy and the United Kingdom.

For investors, the dollar figure is modest in isolation. The more important feature is the structure. Rather than relying on a one-off equipment sale, the agreement is intended to progress from evaluation and clinic demonstrations into recurring quarterly purchases.

That is the commercial model Memphasys needs to prove if Felix is to develop from an interesting reproductive technology into a scalable medical-device platform.

Evaluation first, recurring orders next

TK Biotech will begin with a three-month evaluation and market-introduction period covering product training, demonstrations and early engagement with Polish fertility clinics.

The initial evaluation order is expected to be invoiced during the September 2026 quarter. Assuming the evaluation phase is completed, minimum quarterly purchase commitments are scheduled to begin in the December 2026 quarter and increase materially during the second year.

Revenue will be recognised when products are supplied and invoiced, while cash receipts will depend on the agreed payment terms. That distinction matters because the A$350,000 headline value is not immediate revenue or cash in the bank. It is the minimum contracted value over the commercial term, subject to the agreement progressing through its planned stages.

Exclusivity is also conditional. TK Biotech retains exclusive Polish rights only while meeting its minimum purchasing, regulatory, commercial and market-development obligations. Performance incentives are included to encourage sales above the contracted floor.

This provides Memphasys with some protection against a distributor securing a territory and then leaving Felix to gather dust in the catalogue.

Poland offers a supportive IVF backdrop

The timing is helped by Poland's expanding publicly funded IVF program, introduced in June 2024.

By 31 May 2026, the program was operating through 58 fertility clinics, had qualified more than 51,000 couples and had contributed to 29,806 clinical pregnancies and 15,000 births.

Greater public funding does not automatically translate into Felix sales, but it expands the addressable clinical environment. More treatment cycles can increase demand for technologies that improve laboratory workflows, standardise processes and potentially support better clinical outcomes.

Felix uses electrophoresis and size-exclusion membranes to isolate viable sperm cells without traditional centrifugation. Memphasys says the process is fast, gentle and standardised, while reducing laboratory time and avoiding some of the cellular stress and DNA damage associated with centrifugation.

The investment case still depends on clinics accepting those benefits in practice and purchasing enough cartridges to create repeat revenue.

Local partner brings established clinic relationships

TK Biotech appears to offer more than a sales address and a phone number.

Established in 2001, the company distributes laboratory equipment, diagnostic products and reagents across IVF, diagnostics, life sciences, biotechnology, veterinary medicine and pharmaceuticals. It has a dedicated IVF operation, scientific specialists and technical-service coverage across major Polish cities.

Under the partnership model, TK Biotech will manage local clinic relationships, demonstrations, customer onboarding, training and first-line support. Memphasys will provide technical assistance, approved marketing material and participation in selected clinic meetings, seminars and conferences.

That division of labour reduces the need for Memphasys to build a large direct sales operation in every market. It also places execution in the hands of a distributor that already understands the local IVF sector.

Director of Clinical Partnerships and Growth, Associate Professor Hassan Bakos, said Poland provided a clear pathway from evaluation to recurring quarterly orders. He added that the opportunity originated from direct interest by TK Biotech and progressed rapidly following meetings at the ESHRE conference in London.

TK Biotech Sales Director IVF Anna Maria Pawlak said Felix complemented the distributor's existing portfolio and addressed an important clinical need in Polish IVF laboratories.

European pipeline begins to take shape

Memphasys is also appointing a Director of Commercial Operations - Europe, expected to start in mid-September 2026. The role will support partner onboarding, clinic conversion, key-account management and the eventual development of a broader European team.

The company says it is progressing additional discussions with prospective partners and IVF groups following ESHRE 2026.

Investors should now watch the conversion points rather than the size of the pipeline alone: the September evaluation order, the first minimum quarterly order expected in the December quarter, and evidence that cartridge purchases rise during the second year.

Poland adds another pin to the European map. The next challenge is ensuring those pins produce repeat orders rather than merely decorating the corporate presentation.